Posts Tagged ‘gilead’

Wednesday November 28, 2012 we will have a guest speaker.  Jason King from AIDS Healthcare Foundation will speak on AHF’s advocacy programs.

AHF is engaged in an effort to curb HIV drug pricing in this country, and our main target right now is Gilead Sciences. As you know, Gilead assigned its newest antiretroviral therapy, Stribild, a wholesale acquisition cost (WAC) of $28,500 per year. This is absolutely unconscionable. Despite calls from AIDS organizations, members of the community, and 13 members of Congress for Gilead to practice restraint when pricing its new drug, Gilead proceeded to price Stribild at a value that exceeds most HIV patients’ annual income. Stribild is a “me too” drug, similar to Atripla and Complera, whose therapeutic benefits are not clinically superior to Atripla—an efficacious single-tablet regimen that costs less. There has even been indication in some studies that the drug may be more harmful to the kidneys and liver than drugs in other regimens. Stribild’s price is going to have a deleterious impact on federal-state AIDS Drug Assistance Programs, Medicaid and Medicare—not to mention private insurers. It is anticipated that Stribild will become a new first-line therapy, prescribed to many. Increased utilization of this drug will further burden already unsustainable and insolvent systems. This will hamper patient access to the drug and cause wait lists to rise.

 AHF is banding together with fellow advocacy organizations and unaffiliated activists to bring on the pressure. Our goal is to get Gilead to lower Stribild’s price and extend rebates and cost savings to all payers. We have had much success in the past through collaboration with groups like yours in getting big PHARMA to bend to the will of the community. I have provided some supplemental material attached to this email about Stribild (formerly the “Quad”) for your review. I believe companies like Gilead will only change when facing the might of AIDS community solidarity.

 AHF will provide refreshments.




Read Full Post »

Today the FDA approved Stribild, which until now we’ve been referring to as the
“Quad” for lack of an official name.  Stribild is a single-tablet, four-drug
combination consisting of tenofovir (Viread), emtricitabine (Emtriva),
elvitegravir (a new integrase inhibitor), and cobicistat (a new boosting agent).

Read article CLICK HERE

Read Full Post »

The U.S. Food and Drug Administration (FDA) has approved Truvada as the first prescription drug—to be used daily and in conjunction with condoms and other safer-sex measures—to prevent HIV among those at high risk for the infection.

Truvada’s approval as pre-exposure prophylaxis (PrEP) was announced via statements from both the FDA and Truvada’s manufacturer, Gilead Sciences.

“As part of PrEP, HIV-uninfected individuals who are at high risk will need to take Truvada daily to lower their chances of becoming infected with HIV should they be exposed to the virus,” the FDA said.

“Truvada for PrEP is meant to be used as part of a comprehensive HIV prevention plan that includes risk reduction counseling consistent and correct condom use, regular HIV testing, and screening for and treatment of other sexually-transmitted infections.

Truvada is not a substitute for safer sex practices.”

To read the full article CLICK HERE

Read Full Post »